A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.

British Journal of Cancer
M E BurgeM T Seymour

Abstract

We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma. In phase I, doses were escalated in chemotherapy naïve or pretreated patients to establish maximum tolerated doses (MTD). In phase II, patients were treated at MTD as first-line therapy with the primary end point of RECIST response. Dose levels in phase I were as follows: Level 1: irinotecan 150 mg m-2 on day 1; capecitabine 850 mg m-2 12-hourly on days 1-9. Level 2: as level 1 but capecitabine 1000 mg m-2. Level 3: as level 2 but irinotecan 180 mg m-2. Level 4: as level 3 but capecitabine 1250 mg m-2. In phase I, 21 patients were entered. Maximum tolerated dose was level 3. Dose-limiting toxicities were lethargy, diarrhoea, vomiting and mucositis. In phase II, 31 patients were entered at level 3. During the first six cycles, 13 of these patients underwent dose reduction and three patients stopped treatment for toxicity. A further six patients stopped for progressive disease. The commonest grade 3-4 toxicities were lethargy (20%), diarrhoea (17%), nausea (10%) and anorexia (10%). There were no treatment-related deaths. The response rate was 32% (95% CI 16-52%). Median overall survival was 10...Continue Reading

References

Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A WebbM Meehan
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Nov 12, 2002·Surgical Oncology Clinics of North America·Linda Morris Brown, Susan S Devesa
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Werner ScheithauerDieter Depisch
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M TewesU Vanhoefer
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y S HongJ Y Cho
Nov 3, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S S WöhrerM Hejna
Jan 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M M BornerUNKNOWN Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland
Jun 9, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D W ReaC J A Punt
Jul 1, 2005·The New England Journal of Medicine·Chris TwelvesWerner Scheithauer

❮ Previous
Next ❯

Citations

Jan 15, 2011·Langenbeck's Archives of Surgery·Katja OttMarkus Büchler
Oct 25, 2007·Expert Opinion on Pharmacotherapy·Alicia OkinesDavid Cunningham
Jun 13, 2009·European Journal of Clinical Pharmacology·Michele D MignognaStefania Leuci
Apr 1, 2008·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Katja OttJörg Rüdiger Siewert
Apr 17, 2008·Cancer Chemotherapy and Pharmacology·Smitha S KrishnamurthiScot C Remick
Aug 5, 2011·Drugs·Jaclyn YoongTrevor Leong
Apr 20, 2010·Expert Review of Anticancer Therapy·Fadi S FarhatMarwan G Ghosn

❮ Previous
Next ❯

Methods Mentioned

BETA
contraception

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.